229 Meta-analysis female sex and mortality in SAB 10 47. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med. 2010;123(7):631-637. 48. Horváth A, Dobay O, Sahin-Tóth J, et al. Characterisation of antibiotic resistance, virulence, clonality and mortality in MRSA and MSSA bloodstream infections at a tertiarylevel hospital in Hungary: a 6-year retrospective study. Ann Clin Microbiol Antimicrob. 2020;19(1):17. 49. Hsu LY, Loomba-Chlebicka N, Koh TH, Kang ML, Tan BH, Tambyah PA. EMRSA-15 bacteremia is not associated with a worse outcome compared with bacteremia caused by multidrug-resistant MRSA. Int J Biomed Sci. 2007;3 (2):97-103. 50. Joo EJ, Peck KR, Ha YE, et al. Impact of acute kidney injury on mortality and medical costs in patients with meticillin-resistant Staphylococcus aureus bacteraemia: a retrospective, multicentre observational study. J Hosp Infect. 2013;83(4):300-306. 51. Joost I, Kaasch A, Pausch C, et al. Staphylococcus aureus bacteremia in patients with rheumatoid arthritis— data from the prospective INSTINCT cohort. J Infect. 2017;74(6):575-584. 52. Jorgensen SCJ, Lagnf AM, Bhatia S, Rybak MJ. A new simplified predictive model for mortality in methicillin- resistant Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2019;38(5):843-850. 53. Kempker RR, Farley MM, Ladson JL, Satola S, Ray SM. Association of methicillin-resistant Staphylococcus aureus (MRSA) USA300 genotype with mortality in MRSA bacteremia. J Infect. 2010;61(5):372-381. 54. Kim D, Hong JS, Yoon EJ, et al. Toxic shock syndrome toxin 1-producing methicillinresistant Staphylococcus aureus of clonal complex 5, the New York/Japan epidemic clone, causing a high early-mortality rate in patients with bloodstream infections. Antimicrob Agents Chemother. 2019;63(11):e01362-19. 55. Kim J, Gregson DB, Ross T, Laupland KB. Time to blood culture positivity in Staphylococcus aureus bacteremia: association with 30-day mortality. J Infect. 2010;61(3):197-204. 56. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52(1):192-197. 57. Kim T, Chong YP, Park KH, et al. Clinical and microbiological factors associated with early patient mortality from methicillin-resistant Staphylococcus aureus bacteremia. Korean J Intern Med. 2019;34(1):184-194. 58. Kobayashi D, Yokota K, Takahashi O, Arioka H, Fukui T. A predictive rule for mortality of inpatients with Staphylococcus aureus bacteraemia: a classification and regression tree analysis. Eur J Intern Med. 2014;25(10): 914-918. 59. Lamagni TL, Potz N, Powell D, Pebody R, Wilson J, Duckworth G. Mortality in patients with meticillin-resistant Staphylococcus aureus bacteraemia, England 2004-2005. J Hosp Infect. 2011;77(1):16-20. 60. Laupland KB, Harris PNA, Stewart AG, Edwards F, Paterson DL. Culture-based determinants and outcome of Staphylococcus aureus bloodstream infections. Diagn Microbiol Infect Dis. 2022;104(3):115772. 61. Lee CH, Chien CC, Liu JW. Timing of initiating glycopeptide therapy for methicillinresistant Staphylococcus aureus bacteremia: the impact on clinical outcome. ScientificWorldJournal. 2013;2013:457435.
RkJQdWJsaXNoZXIy MTk4NDMw